Literature DB >> 15294292

Purification and characterization of hepatitis C virus non-structural protein 5A expressed in Escherichia coli.

Luyun Huang1, Elena V Sineva, Michele R S Hargittai, Suresh D Sharma, Mehul Suthar, Kevin D Raney, Craig E Cameron.   

Abstract

We have employed a pET-ubiquitin expression system to produce two his-tagged forms of hepatitis C virus (HCV) non-structural protein 5A (NS5A) in Escherichia coli. One derivative contains the full-length protein extended to include a carboxy-terminal hexahistidine tag; the other derivative contains an amino-terminal hexahistidine tag in place of the 32 amino acid amphipathic helix that mediates membrane association. At least 1 mg of each derivative at a purity of 90% could be produced from a 1-L culture. The purified derivatives produced high titer antibody that recognized both p56 and p58 forms of NS5A in Huh-7.5 cells expressing an HCV subgenomic replicon. The NS5A derivatives were efficiently phosphorylated by casein kinase II, leading to at least 5 mol of phosphate incorporated per mole of protein. Interestingly, this level of phosphorylation did not alter the migration of the protein in an SDS-polyacrylamide gel, suggesting that hyperphosphorylation alone is not sufficient to generate the p58 form of NS5A observed in Huh-7 cells. Neither NS5A derivative was capable of inhibiting the eIF2alpha-phosphorylation activity of the activated form of the double-stranded RNA-activated protein kinase, PKR, suggesting that NS5A phosphorylation may be required for this function of NS5A. However, both unphosphorylated derivatives were shown to interact with NS5B, the HCV RNA-dependent RNA polymerase, in solution by using a novel kinase-protection assay. The availability of purified HCV NS5A will permit rigorous biochemical and biophysical characterization of this protein, ultimately providing insight into the function of this protein during HCV genome replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294292     DOI: 10.1016/j.pep.2004.05.005

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  31 in total

1.  Identification of the oriI-binding site of poliovirus 3C protein by nuclear magnetic resonance spectroscopy.

Authors:  C D Amero; J J Arnold; I M Moustafa; C E Cameron; M P Foster
Journal:  J Virol       Date:  2008-02-27       Impact factor: 5.103

2.  Expanding the proteome of an RNA virus by phosphorylation of an intrinsically disordered viral protein.

Authors:  Daniel G Cordek; Tayler J Croom-Perez; Jungwook Hwang; Michele R S Hargittai; Chennareddy V Subba-Reddy; Qingxia Han; Maria Fernanda Lodeiro; Gang Ning; Thomas S McCrory; Jamie J Arnold; Hasan Koc; Brett D Lindenbach; Scott A Showalter; Craig E Cameron
Journal:  J Biol Chem       Date:  2014-07-16       Impact factor: 5.157

3.  Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins.

Authors:  Hua Huang; Fang Sun; David M Owen; Weiping Li; Yan Chen; Michael Gale; Jin Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-21       Impact factor: 11.205

4.  Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family.

Authors:  Matthew A Gregory; Michael Bobardt; Susan Obeid; Udayan Chatterji; Nigel J Coates; Teresa Foster; Philippe Gallay; Pieter Leyssen; Steven J Moss; Johan Neyts; Mohammad Nur-e-Alam; Jan Paeshuyse; Mahmood Piraee; Dipen Suthar; Tony Warneck; Ming-Qiang Zhang; Barrie Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

5.  Human mitochondrial RNA polymerase: evaluation of the single-nucleotide-addition cycle on synthetic RNA/DNA scaffolds.

Authors:  Eric D Smidansky; Jamie J Arnold; Shelley L Reynolds; Craig E Cameron
Journal:  Biochemistry       Date:  2011-05-12       Impact factor: 3.162

6.  Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.

Authors:  Eisuke Murakami; Michio Imamura; C Nelson Hayes; Hiromi Abe; Nobuhiko Hiraga; Yoji Honda; Atsushi Ono; Keiichi Kosaka; Tomokazu Kawaoka; Masataka Tsuge; Hiroshi Aikata; Shoichi Takahashi; Daiki Miki; Hidenori Ochi; Hirotaka Matsui; Akinori Kanai; Toshiya Inaba; Fiona McPhee; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

7.  DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A.

Authors:  Lotte Coelmont; Xavier Hanoulle; Udayan Chatterji; Carola Berger; Joke Snoeck; Michael Bobardt; Precious Lim; Inge Vliegen; Jan Paeshuyse; Grégoire Vuagniaux; Anne-Mieke Vandamme; Ralf Bartenschlager; Philippe Gallay; Guy Lippens; Johan Neyts
Journal:  PLoS One       Date:  2010-10-27       Impact factor: 3.240

8.  TARGETING THE NS5A PROTEIN OF HCV: AN EMERGING OPTION.

Authors:  D G Cordek; J T Bechtel; A T Maynard; W M Kazmierski; C E Cameron
Journal:  Drugs Future       Date:  2011-09       Impact factor: 0.148

9.  Insight into poliovirus genome replication and encapsidation obtained from studies of 3B-3C cleavage site mutants.

Authors:  Hyung Suk Oh; Harsh B Pathak; Ian G Goodfellow; Jamie J Arnold; Craig E Cameron
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

10.  HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors.

Authors:  Udayan Chatterji; Precious Lim; Michael D Bobardt; Stefan Wieland; Daniel G Cordek; Gregoire Vuagniaux; Francis Chisari; Craig E Cameron; Paul Targett-Adams; Tanya Parkinson; Philippe A Gallay
Journal:  J Hepatol       Date:  2010-04-03       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.